The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Will The Market Size Of The Epkinly Market Progress Through 2030?
The expansion observed in the past can be attributed to a growing occurrence of non-Hodgkin lymphoma, the drawbacks of standard chemotherapy, progress in monoclonal antibody research, a higher number of approvals for targeted oncology drugs, and the existing unmet demands in treating relapsed cancer.
The market expansion during the forecast period is fueled by the increasing embrace of immuno-oncology treatments, the broadening scope of clinical applications for bispecific antibodies, enhanced patient outcome data, a rise in oncology healthcare spending, and the proliferation of specialized cancer centers.
Significant trends expected in the forecast period involve the utilization of bispecific antibody immunotherapies, an expanded presence of t-cell engaging oncology medications, a targeted approach to relapsed and refractory lymphomas, subcutaneous administration of oncology drugs, and personalized treatment strategies for hematologic cancers.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20060&type=smp
What Key Growth Drivers Are Influencing The Epkinly Market?
The future expansion of the epkinly market is expected due to the increasing demand for targeted therapies. These therapies are precise medical interventions designed to inhibit specific disease-driving molecules, particularly in cancers, offering reduced side effects compared to conventional treatments. The proliferation of targeted therapies stems from their capacity to deliver highly effective, individualized care while minimizing adverse reactions. Epkinly (epcoritamab) serves as a targeted therapeutic agent for relapsed or refractory B-cell non-Hodgkin lymphoma, functioning by connecting CD3 on T cells with CD20 on B cells, thereby guiding the immune system to eradicate malignant B cells. As an illustration, the National Health Service, a UK-based government department, reported in October 2024 that during 2023/24, 14.5% of HRT (hormone replacement therapy) items were linked to an HRT prescription prepayment certificate (PPC). By June 2024, this percentage had increased to 21%, contrasting with 9.7% observed in June 2023. Consequently, the escalating demand for targeted therapies is fueling the expansion of the epkinly market.
How Is The Epkinly Market Distributed Across Key Segments?
The epkinly market covered in this report is segmented –
1) By Indication: Relapsed Or Refractory Diffuse Large B-Cell Lymphoma (DLBCL), High-Grade B-Cell Lymphoma (HGBL), Indolent Lymphoma
2) By Route Of Administration: Intravenous (IV), Subcutaneous (SC)
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, Online Pharmacies
Which Trends Are Shaping The Epkinly Market Landscape?
A major trend in the epkinly market includes obtaining regulatory approvals for innovative therapies, such as bispecific antibody therapies, to enhance treatment effectiveness and broaden therapeutic choices. Bispecific antibody therapies are a form of immunotherapy involving antibodies engineered to simultaneously bind to two different antigens or targets. For instance, in June 2024, AbbVie Inc., a US-based biotech company, received FDA approval for EPKINLY (epcoritamab-bysp), marking it as the first bispecific antibody for adults with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. This cutting-edge treatment engages the immune system by targeting CD20 and CD3, resulting in an impressive overall response rate of 82% in clinical trials. Administered subcutaneously with a step-up dosing regimen, EPKINLY provides a new option for patients facing limited alternatives. This approval signifies a significant advancement in the management of follicular lymphoma, offering hope for improved patient outcomes.
Which Companies Are Influencing The Epkinly Market?
Major companies operating in the epkinly market are AbbVie Inc., Genmab A/S.
Access The Complete Epkinly Market Report:
https://www.thebusinessresearchcompany.com/report/epkinly-global-market-report
Which Region Has The Strongest Presence In The Epkinly Market?
North America was the largest region in the epkinly market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the epkinly market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model